Generic Name: vorinostat

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Merck

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

 


General Info

Zolinza is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.


Dosage

Dosing Info:

Zolinza is a capsule taken once daily with food.


Side Effects

Common side effects include diarrhea, fatigue, nausea and loss of appetite. Zolinza can cause depletion of red blood cells (anemia) and platelets (thrombocytopenia), which can lead to easy bleeding. Potential severe side effects include blood clots, gastrointestinal damage and high blood glucose. Zolinza may cause fetal harm if used during pregnancy.


For More Info: https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf

Patient Assistance Program Info: http://www.merckhelps.com/ZOLINZA

Last Reviewed: November 29, 2018